{'52WeekChange': 0.92460644,
 'SandP52WeekChange': 0.0644362,
 'address1': '7555 Gateway Boulevard',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 23.26,
 'askSize': 800,
 'averageDailyVolume10Day': 421962,
 'averageVolume': 537688,
 'averageVolume10days': 421962,
 'beta': 1.643137,
 'beta3Year': None,
 'bid': 23.23,
 'bidSize': 900,
 'bookValue': 5.408,
 'category': None,
 'circulatingSupply': None,
 'city': 'Newark',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 24.635,
 'dayLow': 22.82,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -5.458,
 'enterpriseToRevenue': 5253.218,
 'enterpriseValue': 1013871040,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '510 742 3401',
 'fiftyDayAverage': 24.053572,
 'fiftyTwoWeekHigh': 27.97,
 'fiftyTwoWeekLow': 9.88,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 46180779,
 'forwardEps': -3.56,
 'forwardPE': -6.525281,
 'fromCurrency': None,
 'fullTimeEmployees': 193,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.014479999,
 'heldPercentInstitutions': 0.95682,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/revance.com',
 'longBusinessSummary': 'Revance Therapeutics, Inc., a biotechnology company, '
                        'engages in the development, manufacture, and '
                        'commercialization of neuromodulators for various '
                        'aesthetic and therapeutic indications in the United '
                        "States and internationally. The company's lead drug "
                        'candidate is DaxibotulinumtoxinA for injection (DAXI) '
                        'which competed phase 3 clinical trials for the '
                        'treatment of glabellar (frown) lines and cervical '
                        'dystonia; in phase 2 clinical trials to treat adult '
                        'upper limb spasticity and plantar fasciitis, and in '
                        'pre-clinical trials to treat chronic migraine. It is '
                        'also developing DAXI for forehead lines, lateral '
                        'canthal lines, and upper facial lines that is in '
                        'phase 2 clinical trials; DaxibotulinumtoxinA Topical '
                        'for therapeutic and aesthetic applications; and '
                        'OnabotulinumtoxinA, a biosimilar to BOTOX. The '
                        'company has a collaboration agreement with Mylan '
                        'Ireland Limited for the development, manufacture, and '
                        'commercialization of a biosimilar to BOTOX; and '
                        'collaboration and license agreement with Mylan N.V. '
                        'for the development and regulatory approval of a '
                        'biosimilar to BOTOX. The company was formerly known '
                        'as Essentia Biosystems, Inc. and changed its name to '
                        'Revance Therapeutics, Inc. in April 2005. Revance '
                        'Therapeutics, Inc. was founded in 1999 and is '
                        'headquartered in Newark, California.',
 'longName': 'Revance Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 1328964992,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_9344828',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -186058000,
 'nextFiscalYearEnd': 1640908800,
 'open': 23.18,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.46,
 'phone': '510 742 3400',
 'previousClose': 23.5,
 'priceHint': 2,
 'priceToBook': 4.295488,
 'priceToSalesTrailing12Months': 6885.829,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 24.635,
 'regularMarketDayLow': 22.82,
 'regularMarketOpen': 23.18,
 'regularMarketPreviousClose': 23.5,
 'regularMarketPrice': 23.18,
 'regularMarketVolume': 348494,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 57209000,
 'sharesPercentSharesOut': 0.1306,
 'sharesShort': 7471258,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 6938514,
 'shortName': 'Revance Therapeutics, Inc.',
 'shortPercentOfFloat': 0.15010001,
 'shortRatio': 11.39,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'RVNC',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -3.999,
 'twoHundredDayAverage': 20.854641,
 'volume': 348494,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.revance.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94560'}